Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation

K. Huber, S. J. Connolly, A. Kher, F. Christory, G. A. Dan, R. Hatala, R. Kiss, B. Meier, B. Merkely, B. Pieske, T. Potpara, J. Stȩpińska, N. Vene Klun, D. Vinereanu, P. Widimský

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, and is the most prevalent factor for cardioembolic stroke. Vitamin K antagonists (VKAs) have been the standard of care for stroke prevention in patients with AF since the early 1990s. They are very effective for the prevention of cardioembolic stroke, but are limited by factors such as drug-drug interactions, food interactions, slow onset and offset of action, haemorrhage and need for routine anticoagulation monitoring to maintain a therapeutic international normalised ratio (INR). Multiple new oral anticoagulants have been developed as potential replacements for VKAs for stroke prevention in AF. Most are small synthetic molecules that target thrombin (e.g. dabigatran etexilate) or factor Xa (e.g. rivaroxaban, apixaban, edoxaban, betrixaban, YM150). These drugs have predictable pharmacokinetics that allow fixed dosing without routine laboratory monitoring. Dabigatran etexilate, the first of these new oral anticoagulants to be approved by the United States Food and Drug Administration and the European Medicines Agency for stroke prevention in patients with non-valvular AF, represents an effective and safe alternative to VKAs. Under the auspices of the Regional Anticoagulation Working Group, a multidisciplinary group of experts in thrombosis and haemostasis from Central and Eastern Europe, an expert panel with expertise in AF convened to discuss practical, clinically important issues related to the long-term use of dabigatran for stroke prevention in non-valvular AF. The practical information reviewed in this article will help clinicians make appropriate use of this new therapeutic option in daily clinical practice.

Original languageEnglish
Pages (from-to)516-526
Number of pages11
JournalInternational Journal of Clinical Practice
Volume67
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Atrial Fibrillation
Stroke
Vitamin K
Anticoagulants
Food-Drug Interactions
Eastern Europe
Factor Xa
International Normalized Ratio
Thromboembolism
Therapeutic Uses
United States Food and Drug Administration
Standard of Care
Hemostasis
Drug Interactions
Thrombin
Pharmaceutical Preparations
Dabigatran
Thrombosis
Pharmacokinetics
Hemorrhage

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Huber, K., Connolly, S. J., Kher, A., Christory, F., Dan, G. A., Hatala, R., ... Widimský, P. (2013). Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. International Journal of Clinical Practice, 67(6), 516-526. https://doi.org/10.1111/ijcp.12147

Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. / Huber, K.; Connolly, S. J.; Kher, A.; Christory, F.; Dan, G. A.; Hatala, R.; Kiss, R.; Meier, B.; Merkely, B.; Pieske, B.; Potpara, T.; Stȩpińska, J.; Klun, N. Vene; Vinereanu, D.; Widimský, P.

In: International Journal of Clinical Practice, Vol. 67, No. 6, 06.2013, p. 516-526.

Research output: Contribution to journalArticle

Huber, K, Connolly, SJ, Kher, A, Christory, F, Dan, GA, Hatala, R, Kiss, R, Meier, B, Merkely, B, Pieske, B, Potpara, T, Stȩpińska, J, Klun, NV, Vinereanu, D & Widimský, P 2013, 'Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation', International Journal of Clinical Practice, vol. 67, no. 6, pp. 516-526. https://doi.org/10.1111/ijcp.12147
Huber, K. ; Connolly, S. J. ; Kher, A. ; Christory, F. ; Dan, G. A. ; Hatala, R. ; Kiss, R. ; Meier, B. ; Merkely, B. ; Pieske, B. ; Potpara, T. ; Stȩpińska, J. ; Klun, N. Vene ; Vinereanu, D. ; Widimský, P. / Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. In: International Journal of Clinical Practice. 2013 ; Vol. 67, No. 6. pp. 516-526.
@article{4ac1399dfb5f498b968d9921bf21ef9f,
title = "Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation",
abstract = "Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, and is the most prevalent factor for cardioembolic stroke. Vitamin K antagonists (VKAs) have been the standard of care for stroke prevention in patients with AF since the early 1990s. They are very effective for the prevention of cardioembolic stroke, but are limited by factors such as drug-drug interactions, food interactions, slow onset and offset of action, haemorrhage and need for routine anticoagulation monitoring to maintain a therapeutic international normalised ratio (INR). Multiple new oral anticoagulants have been developed as potential replacements for VKAs for stroke prevention in AF. Most are small synthetic molecules that target thrombin (e.g. dabigatran etexilate) or factor Xa (e.g. rivaroxaban, apixaban, edoxaban, betrixaban, YM150). These drugs have predictable pharmacokinetics that allow fixed dosing without routine laboratory monitoring. Dabigatran etexilate, the first of these new oral anticoagulants to be approved by the United States Food and Drug Administration and the European Medicines Agency for stroke prevention in patients with non-valvular AF, represents an effective and safe alternative to VKAs. Under the auspices of the Regional Anticoagulation Working Group, a multidisciplinary group of experts in thrombosis and haemostasis from Central and Eastern Europe, an expert panel with expertise in AF convened to discuss practical, clinically important issues related to the long-term use of dabigatran for stroke prevention in non-valvular AF. The practical information reviewed in this article will help clinicians make appropriate use of this new therapeutic option in daily clinical practice.",
author = "K. Huber and Connolly, {S. J.} and A. Kher and F. Christory and Dan, {G. A.} and R. Hatala and R. Kiss and B. Meier and B. Merkely and B. Pieske and T. Potpara and J. Stȩpińska and Klun, {N. Vene} and D. Vinereanu and P. Widimsk{\'y}",
year = "2013",
month = "6",
doi = "10.1111/ijcp.12147",
language = "English",
volume = "67",
pages = "516--526",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation

AU - Huber, K.

AU - Connolly, S. J.

AU - Kher, A.

AU - Christory, F.

AU - Dan, G. A.

AU - Hatala, R.

AU - Kiss, R.

AU - Meier, B.

AU - Merkely, B.

AU - Pieske, B.

AU - Potpara, T.

AU - Stȩpińska, J.

AU - Klun, N. Vene

AU - Vinereanu, D.

AU - Widimský, P.

PY - 2013/6

Y1 - 2013/6

N2 - Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, and is the most prevalent factor for cardioembolic stroke. Vitamin K antagonists (VKAs) have been the standard of care for stroke prevention in patients with AF since the early 1990s. They are very effective for the prevention of cardioembolic stroke, but are limited by factors such as drug-drug interactions, food interactions, slow onset and offset of action, haemorrhage and need for routine anticoagulation monitoring to maintain a therapeutic international normalised ratio (INR). Multiple new oral anticoagulants have been developed as potential replacements for VKAs for stroke prevention in AF. Most are small synthetic molecules that target thrombin (e.g. dabigatran etexilate) or factor Xa (e.g. rivaroxaban, apixaban, edoxaban, betrixaban, YM150). These drugs have predictable pharmacokinetics that allow fixed dosing without routine laboratory monitoring. Dabigatran etexilate, the first of these new oral anticoagulants to be approved by the United States Food and Drug Administration and the European Medicines Agency for stroke prevention in patients with non-valvular AF, represents an effective and safe alternative to VKAs. Under the auspices of the Regional Anticoagulation Working Group, a multidisciplinary group of experts in thrombosis and haemostasis from Central and Eastern Europe, an expert panel with expertise in AF convened to discuss practical, clinically important issues related to the long-term use of dabigatran for stroke prevention in non-valvular AF. The practical information reviewed in this article will help clinicians make appropriate use of this new therapeutic option in daily clinical practice.

AB - Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, and is the most prevalent factor for cardioembolic stroke. Vitamin K antagonists (VKAs) have been the standard of care for stroke prevention in patients with AF since the early 1990s. They are very effective for the prevention of cardioembolic stroke, but are limited by factors such as drug-drug interactions, food interactions, slow onset and offset of action, haemorrhage and need for routine anticoagulation monitoring to maintain a therapeutic international normalised ratio (INR). Multiple new oral anticoagulants have been developed as potential replacements for VKAs for stroke prevention in AF. Most are small synthetic molecules that target thrombin (e.g. dabigatran etexilate) or factor Xa (e.g. rivaroxaban, apixaban, edoxaban, betrixaban, YM150). These drugs have predictable pharmacokinetics that allow fixed dosing without routine laboratory monitoring. Dabigatran etexilate, the first of these new oral anticoagulants to be approved by the United States Food and Drug Administration and the European Medicines Agency for stroke prevention in patients with non-valvular AF, represents an effective and safe alternative to VKAs. Under the auspices of the Regional Anticoagulation Working Group, a multidisciplinary group of experts in thrombosis and haemostasis from Central and Eastern Europe, an expert panel with expertise in AF convened to discuss practical, clinically important issues related to the long-term use of dabigatran for stroke prevention in non-valvular AF. The practical information reviewed in this article will help clinicians make appropriate use of this new therapeutic option in daily clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84878106095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878106095&partnerID=8YFLogxK

U2 - 10.1111/ijcp.12147

DO - 10.1111/ijcp.12147

M3 - Article

VL - 67

SP - 516

EP - 526

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 6

ER -